The use of diuretics in varying degrees of renal impairment: an overview.
Administration of diuretics during acute renal failure in animals has been demonstrated to be of value with mannitol and/or loop-blocking diuretics, furosemide or ethacrynic acid. There is evidence that if these drugs are given very early in the controlled experimental environment that there will be some beneficial effect in maintaining renal function. However, in man the temporal relationship between the acute onset and the successful response to the administration of the drugs is, at best, coincidental and the use of diuretics in acute renal failure may not produce the same results as seen in the laboratory. One of the best guides to the underlying disease when there is acute decompensation in renal function is the utility of the renal failure index which utilizes urine and plasma sodium and urine and plasma creatinine ratios. Large doses of loop-blocking diuretics can be of benefit in patients with mild to moderate chronic renal insufficiency and fluid retention and/or hypertension. When renal insufficiency is severe in the pre-dialysis setting, furosemide, bumetanide or muzolimine may be of some benefit; however, as renal failure worsens the response of the kidney is sluggish and it is wise to begin to dialyze when glomerular filtration deteriorates below 5 ml per minute.
D058186:Acute Kidney Injury / Q000188:drug therapy*; D002034:Bumetanide / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008353:Mannitol / Q000627:therapeutic use; D009156:Muzolimine / Q000627:therapeutic use
D004232:Diuretics; D009156:Muzolimine; D002034:Bumetanide; D008353:Mannitol; D005665:Furosemide; D004976:Ethacrynic Acid